Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
Legionnaires disease Indication Strategy Report 2026: Legionella LpxC, Trials and Deals
23 July 2026
2026 Legionnaires disease strategy: epidemiology, Legionella LpxC biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Q fever Indication Strategy Report 2026: Coxiella DNA gyrase, Trials and Deals
23 July 2026
2026 Q fever strategy: epidemiology, Coxiella DNA gyrase biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized…
Latest Hotspot
8 min read
Brucellosis Indication Strategy Report 2026: Brucella DNA gyrase, Trials and Deals
23 July 2026
2026 Brucellosis strategy: epidemiology, Brucella DNA gyrase biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Melioidosis Indication Strategy Report 2026: Burkholderia LpxC, Trials and Deals
23 July 2026
2026 Melioidosis strategy: epidemiology, Burkholderia LpxC biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Visceral leishmaniasis Indication Strategy Report 2026: Leishmania CYP51, Trials and Deals
23 July 2026
2026 Visceral leishmaniasis strategy: epidemiology, Leishmania CYP51 biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Cutaneous leishmaniasis Indication Strategy Report 2026: Leishmania CYP51, Trials and Deals
23 July 2026
2026 Cutaneous leishmaniasis strategy: epidemiology, Leishmania CYP51 biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Toxoplasmosis Indication Strategy Report 2026: Toxoplasma DHFR, Trials and Deals
23 July 2026
2026 Toxoplasmosis strategy: epidemiology, Toxoplasma DHFR biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Babesiosis Indication Strategy Report 2026: Babesia DHODH, Trials and Deals
23 July 2026
2026 Babesiosis strategy: epidemiology, Babesia DHODH biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized…
Latest Hotspot
8 min read
Onchocerciasis Indication Strategy Report 2026: Wolbachia, Trials and Deals
23 July 2026
2026 Onchocerciasis strategy: epidemiology, Wolbachia biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized…
Latest Hotspot
8 min read
Schistosomiasis Indication Strategy Report 2026: Sm14, Trials and Deals
23 July 2026
2026 Schistosomiasis strategy: epidemiology, Sm14 biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized with…
Latest Hotspot
8 min read
African trypanosomiasis Indication Strategy Report 2026: Trypanosoma protease, Trials and Deals
23 July 2026
2026 African trypanosomiasis strategy: epidemiology, Trypanosoma protease biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Lymphatic filariasis Indication Strategy Report 2026: Wolbachia, Trials and Deals
23 July 2026
2026 Lymphatic filariasis strategy: epidemiology, Wolbachia biology, clinical competition, recent deals, unmet need and market attractiveness.